221 related articles for article (PubMed ID: 8262670)
21. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
Begleiter A; Leith MK; Curphey TJ
Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837
[TBL] [Abstract][Full Text] [Related]
22. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
Robertson N; Stratford IJ; Houlbrook S; Carmichael J; Adams GE
Biochem Pharmacol; 1992 Aug; 44(3):409-12. PubMed ID: 1510692
[TBL] [Abstract][Full Text] [Related]
23. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Jaffar M; Naylor MA; Robertson N; Lockyer SD; Phillips RM; Everett SA; Adams GE; Stratford IJ
Anticancer Drug Des; 1998 Mar; 13(2):105-23. PubMed ID: 9524554
[TBL] [Abstract][Full Text] [Related]
24. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase.
Phillips RM
Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133
[TBL] [Abstract][Full Text] [Related]
25. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
[TBL] [Abstract][Full Text] [Related]
26. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
27. Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.
Samuni AM; DeGraff W; Krishna MC; Mitchell JB
Mol Cell Biochem; 2002; 234-235(1-2):327-33. PubMed ID: 12162451
[TBL] [Abstract][Full Text] [Related]
28. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P
Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456
[TBL] [Abstract][Full Text] [Related]
29. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia.
Begleiter A; Robotham E; Leith MK
Mol Pharmacol; 1992 Apr; 41(4):677-82. PubMed ID: 1373799
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
Baas P; Michielsen C; Oppelaar H; van Zandwijk N; Stewart FA
Int J Cancer; 1994 Mar; 56(6):880-5. PubMed ID: 8119776
[TBL] [Abstract][Full Text] [Related]
32. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions.
Begleiter A; Leith MK
Mol Pharmacol; 1993 Jul; 44(1):210-5. PubMed ID: 8341273
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.
Siegel D; Gibson NW; Preusch PC; Ross D
Cancer Res; 1990 Dec; 50(23):7483-9. PubMed ID: 1701346
[TBL] [Abstract][Full Text] [Related]
34. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
35. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
Lambert PA; Kang Y; Greaves B; Perry RR
J Surg Res; 1998 Dec; 80(2):177-81. PubMed ID: 9878310
[TBL] [Abstract][Full Text] [Related]
36. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
38. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
Skibo EB; Xing C; Dorr RT
J Med Chem; 2001 Oct; 44(22):3545-62. PubMed ID: 11606119
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
Cummings J; Spanswick VJ; Gardiner J; Ritchie A; Smyth JF
Biochem Pharmacol; 1998 Feb; 55(3):253-60. PubMed ID: 9484790
[TBL] [Abstract][Full Text] [Related]
40. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.
Wang X; Doherty GP; Leith MK; Curphey TJ; Begleiter A
Br J Cancer; 1999 Jun; 80(8):1223-30. PubMed ID: 10376975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
